Yanli Jin
- Hematology top 5%
- Chronic Myeloid Leukemia Treatments 21
- Acute Myeloid Leukemia Research 6
- Molecular Biology top 10%
- Cancer-related gene regulation 8
- Histone Deacetylase Inhibitors Research 6
- Epigenetics and DNA Methylation 5
- Protein Degradation and Inhibitors 4
- Genetics top 10%
- Chronic Lymphocytic Leukemia Research 6
- Cancer Research top 10%
-
- Eosinophilic Disorders and Syndromes 6
- Partner nations
- ChinaUnited StatesItaly
In The Last Decade
Yanli Jin
43 papers receiving 1.5k citations
Peers
Comparison fields: 5 of 93
- Hematology 299
- Complementary and alternative medicine 151
- Molecular Biology 1.1k
- Genetics 135
- Cancer Research 179
Countries citing papers authored by Yanli Jin
This map shows the geographic impact of Yanli Jin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yanli Jin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yanli Jin more than expected).
Fields of papers citing papers by Yanli Jin
This network shows the impact of papers produced by Yanli Jin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yanli Jin. The network helps show where Yanli Jin may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Yanli Jin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2024 | 5 | |
| 4 | 2023 | 2 | |
| 5 | 2022 | 43 | |
| 6 | 2020 | 14 | |
| 7 | 2018 | 26 | |
| 8 | 2017 | 27 | |
| 9 | 2017 | 48 | |
| 10 | 2017 | 33 | |
| 11 | 2016 | 37 | |
| 12 | 2014 | 17 | |
| 13 | 2010 | 261 | |
| 14 | 2010 | 25 | |
| 15 | 2010 | 17 | |
| 16 | 2010 | 50 | |
| 17 | 2009 | 98 | |
| 18 | 2009 | 15 | |
| 19 | 2009 | 21 | |
| 20 | 2004 | 61 |
About Yanli Jin
Yanli Jin is a scholar working on Hematology, Genetics and Rheumatology, having authored 45 papers that have together received 1.5k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (21 papers), Cancer-related gene regulation (8 papers), Chronic Lymphocytic Leukemia Research (6 papers), Histone Deacetylase Inhibitors Research (6 papers), Acute Myeloid Leukemia Research (6 papers), Eosinophilic Disorders and Syndromes (6 papers), Epigenetics and DNA Methylation (5 papers) and Protein Degradation and Inhibitors (4 papers). The work is most often cited by research in Hematology (299 citations), Complementary and alternative medicine (151 citations) and Molecular Biology (1.1k citations). Yanli Jin has collaborated with scholars based in China, United States and Italy. Frequent co-authors include Jingxuan Pan, Zhongzheng Lu, Xin Du, Jingfeng Zhou, Bei Jin, Ke Ding, Yongbin Wu, Yingrong Lai, Chun Chen and Jing Zhou. Their work appears in journals such as Cancer Letters, Clinical Cancer Research, Cancer Research, Oncogene and Molecular Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.